Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's DiseaseGlobeNewsWire • 06/06/22
Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)GlobeNewsWire • 06/03/22
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALSGlobeNewsWire • 06/03/22
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/02/22
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary EndpointsBusiness Wire • 06/01/22
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple SclerosisBusiness Wire • 05/05/22
Called to Account: Drug companies are making an accounting change after the SEC cracked down on BiogenMarket Watch • 05/03/22
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping DownInvestorPlace • 05/03/22